$5.65M Net Loss for Cellectar Biosciences in Q1, Cash Dwindles to $8.3M Before Financing
CLRB sits 19% above its 52-week low of $2.43 on light trading volume (0.2× avg).
Summary
Cellectar Biosciences reported a net loss of $5.65 million for the first quarter of 2026, alongside a critical cash position of $8.3 million as of March 31, 2026. This financial update precedes the approximately $31 million in net proceeds from a highly dilutive financing completed in May, which was previously detailed in SEC filings on May 6 and May 8. The substantial net loss and low cash balance are highly material for a company of this size, underscoring its reliance on the recent capital raise to fund operations into Q2 2027. The company's 10-Q, filed later today, is expected to further elaborate on these financial challenges, including a reiteration of substantial doubt about its ability to continue as a going concern. Traders will closely watch the company's cash burn and clinical development progress.
At the time of this announcement, CLRB was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $2.43 to $20.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.